Eli Lilly Takes Whistleblower Law Challenge to Supreme Court

In a bold move that could reshape whistleblower litigation across America, Indianapolis pharmaceutical giant Eli Lilly has petitioned the U.S. Supreme Court to fundamentally restrict the False Claims Act’s whistleblower provisions, arguing that the Civil War-era statute unconstitutionally empowers private citizens to act as federal prosecutors.

The challenge stems from a costly legal battle over Lilly’s Medicaid pricing practices that culminated in a $183 million judgment against the company. Lilly’s petition marks one of the most significant constitutional challenges to the qui tam provisions that have become a cornerstone of federal fraud enforcement.

At the heart of the case is Ronald Streck’s 2014 False Claims Act lawsuit alleging that Lilly misreported its Average Manufacturer Price figures used to calculate Medicaid rebates. In August 2022, a federal jury sided with Streck, initially awarding approximately $61 million in damages. Under the False Claims Act’s trebling provision, that amount was tripled to roughly $183 million. The Seventh Circuit Court of Appeals subsequently upheld the jury’s core findings on falsity, materiality, and scienter.

Lilly’s Supreme Court petition raises profound constitutional questions about who has the authority to enforce federal law. In its initial extension request, the company provocatively framed the issue as whether “private bounty hunters, accountable to no one but themselves, may enforce federal law on behalf of and in the name of the United States.” This language signals Lilly’s intention to challenge the fundamental legitimacy of the qui tam mechanism itself.

The pharmaceutical company is advancing two primary arguments. First, Lilly contends that the False Claims Act’s qui tam structure violates constitutional principles by allowing private individuals to pursue enforcement actions without presidential oversight. Second, the company challenges fee-shifting provisions that can force defendants to pay relators’ legal expenses even when the government declines to intervene in a case.

The stakes extend far beyond Lilly’s individual circumstances. According to the Justice Department, False Claims Act cases returned a record $6.8 billion to taxpayers in fiscal year 2025, with qui tam lawsuits contributing significantly to that total. Any Supreme Court decision limiting whistleblower provisions or altering fee-shifting rules could dramatically change incentives for potential whistleblowers and impact how aggressively governments pursue fraud recoveries.

Streck’s legal team, which persisted with the case after the federal government declined to intervene, argues that their success demonstrates precisely why relators are vital in combating fraud against public programs. The substantial judgment, they maintain, returned much-needed funds to Medicaid and validated the whistleblower mechanism.

On the opposing side, business advocacy groups have long criticized the False Claims Act as enabling overreaching private prosecutions that create regulatory uncertainty for companies working with federal programs. Organizations like the Washington Legal Foundation have actively pushed courts to narrow the statute’s application through amicus briefs and related appeals.

The pharmaceutical industry, in particular, has frequently found itself targeted by False Claims Act litigation, with cases involving issues ranging from off-label marketing to kickbacks and pricing practices. Lilly’s challenge could provide the industry with a potential pathway to limit such exposure if successful.

Justice Amy Coney Barrett has already granted Lilly an extension until March 21, 2026, to file its formal certiorari petition. This extended timeline gives the company additional time to refine its constitutional arguments before asking the justices to take the case.

If the Supreme Court agrees to hear Lilly’s challenge, its ruling could fundamentally alter how whistleblower lawsuits proceed and potentially restrict a mechanism that federal and state governments have relied upon to recover billions in fraudulently obtained funds. The case represents one of the most significant potential shifts in False Claims Act jurisprudence in decades, with implications that would resonate across healthcare, defense contracting, and other sectors where federal spending is substantial.